15.69
+0.008(+0.05%)
Currency In USD
Address
2100 Powell Street
EmeryVille, CA 94608
United States of America
Phone
510 848 5100
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
405
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Ryan Spencer | Chief Executive Officer & Director | 1.48M | 1978 |
| Kelly MacDonald | Senior VP & CFO | 733,501 | 1984 |
| John Slebir | Senior VP & General Counsel | 809,129 | 1966 |
| Robert Janssen | Chief Medical Officer and Senior Vice President of Clinical Development, Medical & Regulatory Affairs | 827,719 | 1954 |
| David F. Novack | President & Chief Operating Officer | 965,313 | 1962 |
| Dong Yu | Senior Vice President of Research | 0 | N/A |
| Donn Casale | Senior VP & Chief Commercial Officer | 0 | N/A |
| Jeff Coon | Senior VP & Chief Human Resources Officer | 0 | 1963 |
| Joseph Metzinger | VP & Chief Accounting Officer | 0 | 1984 |
| Paul Cox | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.